Tonix Pharmaceuticals comments on Long COVID definition conferences

Tonix Pharmaceuticals commented on two recent meetings sponsored by the National Academies of Sciences, Engineering, and Medicine in Washington, D.C. relating to the definition of Long COVID and to features of Long COVID that overlap with previously recognized infection-associated chronic conditions. Tonix Pharmaceuticals recognizes the potential benefits of defining subgroups of Long COVID patients based on their symptoms and recognizes the subgroup of Long COVID patients with symptoms that overlap with fibromyalgia. Tonix’s experience advancing TNX-102 SL as a treatment for fibromyalgia is the company’s motivation for undertaking the development of TNX-102 SL for the management of Fibromyalgia-type Long COVID. In April, the company completed enrollment of 63 participants in a Phase 2 proof-of-concept study of TNX-102 SL for fibromyalgia-type Long COVID. Topline results from the trial are expected in Q3. In addition, the company presented its analysis of a Fibromyalgia-type Long COVID subgroup that provided real-world evidence that the majority of Long COVID patients present with a constellation of symptoms that overlap with fibromyalgia and CFS/ME. Fibromyalgia-type Long COVID, like fibromyalgia and CFS/ME, appears to be both a subgroup of Long COVID and one of several chronic overlapping pain conditions that have in common the neurological process called central and peripheral sensitization, which is increasingly known by the term nociplastic pain.